DM Intelligence Secures Nearly RMB 10 Million in Angel Funding Led by Guangzhou Nanshan Venture Investment Fund

Investment Circle (ID: pedaily2012) reported on April 25 that, according to 36Kr, the R&DCollaborative AI-Driven Novel DrugsR&D Company——Guangzhou DM Intelligence Ltd. (DM Intelligence, hereinafter referred to as “DM Intelligence”)Completion AnnouncedAngel round financing of nearly RMB 10 million, invested by Guangzhou Nanshan Venture Capital Fund.Following this round of financing, DM Intelligence will continueEnhance the development of the core platform (AI-Driven New Drug Discovery Platform) and accelerate the preclinical advancement of AI-based drug candidates in the pipeline.

Leveraging AI, DM Intelligence has established a comprehensive algorithmic model from multiple dimensions, significantly enhancing screening efficiency to identify novel and diverse active compounds, while implementing global patent strategies. Currently, the company focuses onFocus on oncology, neurodegeneration, infection, and autoimmunitysmall-molecule targeted drug pipeline with validated candidates urgently awaiting market launch. After more than two years of development, the company has developedOver 10 internal pipelines and 5 external collaborative pipelines.Notably, its Parkinson’s disease pipeline is advancing rapidly, with superior trial results compared to peer investigational drugs. DM Intelligence has secured global patent protection for multiple novel-structure compounds identified through AI screening.

Xie Weidong, Founder of DM Intelligencestated that the company will next focus its investments on building an AI-driven drug discovery platform and accelerate the development of key pipelines, including those for Parkinson’s disease. It was reported that Dr. Xie Weidong graduated from Imperial College London and has previously worked at academic research institutions, leading pharmaceutical companies both in China and abroad, and overseas healthcare investment firms.With nearly 30 years of experience in pharmaceutical R&D and new drug evaluation, with experience in the selection and value assessment of innovative drug targets.

It is worth mentioning that, asGuangzhou Nanshan Venture Capital Fund, the investor in this round, is composed ofAcademician of the Chinese Academy of Engineering, Zhong NanshanLed by,Guangdong Nanshan Institute of Pharmaceutical InnovationAs the lead institution, it established a technology transfer investment fund in collaboration with multiple institutions.

Chen Weiyu, Manager of Guangzhou Nanshan Venture Capital FundIt is believed that, at present, the pipeline of lead compounds targeting novel indications such as tumors and neurodegenerative diseases holds significant market value, and the DM Intelligence team has demonstrated corresponding capabilities in this area.